Emanuele Ostuni, Artbio CEO

Art­bio rais­es $90M as ra­dio­phar­ma field finds its foot­ing

An­oth­er ra­dio­phar­ma start­up is adding to the field’s buzz with a $90 mil­lion Se­ries A that it plans to use to get in­to the clin­ic and ex­pand its pipeline to five pro­grams.

Art­bio, a transat­lantic biotech work­ing on al­pha ra­di­oli­gand ther­a­pies, said Thurs­day morn­ing that the fi­nanc­ing will bankroll a Phase I next year in PS­MA-di­rect­ed prostate can­cer, which is the same in­di­ca­tion as No­var­tis’ Plu­vic­to and Con­ver­gent Ther­a­peu­tics, an­oth­er start­up that an­nounced a Se­ries A of the same size in May.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.